Cytological cell blocks: Predictors of squamous cell carcinoma and adenocarcinoma subtypes

Diagnostic Cytopathology

Volumn 40, Issue 5, 2012, Pages 380-387

  Loukeris, Kristina ^a   Vazquez, Madeline F ^b   Sica, Gabriel ^c   Wagner, Patrick ^a   Yankelevitz, David F ^d   Henschke, Claudia I ^d   Cham, Matthew D ^d   Saqi, Anjali ^e  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b CBL Path ^*  (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e Department of Medicine   (United States)

Author keywords

cell blocks; CT guided fine needle aspiration biopsy; fine needle aspiration; lung carcinoma; non small carcinoma

Indexed keywords

ADENOCARCINOMA; ARTICLE; CANCER CLASSIFICATION; CELL BLOCK; CELL STRUCTURE; CELLULAR PARAMETERS; CYTOLOGY; DIAGNOSTIC PROCEDURE; HUMAN; LUNG CARCINOMA; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; BIOPSY, FINE-NEEDLE; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; FOLLOW-UP STUDIES; HISTOCYTOLOGICAL PREPARATION TECHNIQUES; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; SENSITIVITY AND SPECIFICITY;

EID: 84860646809     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21519     Document Type: Article

References (16)

1. Felip E, Santarpia M, Rosell R,. Emerging drugs for non-small-cell lung cancer. Exp Opin Emerg Drugs 2007; 12: 449-460. (Pubitemid 47527047)
2. Di Costanzo F, Mazzoni F, Micol Mela M, et al. Bevacizumab in non-small cell lung cancer. Drugs 2008; 68: 737-746. (Pubitemid 351550528)
3. Renshaw AA, Voytek TM, Haja J, Wilbur DC,. Distinguishing small cell carcinoma from non-small cell carcinoma of the lung: Correlating cytologic features and performance in the College of American Pathologists Non-Gynecologic Cytology Program. Arch Pathol Lab Med 2005; 129: 619-623. (Pubitemid 40616964)
4. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537. (Pubitemid 41540110)
5. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 3238-3247. (Pubitemid 41103678)
6. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597. (Pubitemid 41079796)
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132. (Pubitemid 41058344)
8. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550. (Pubitemid 44917502)
9. Gal AA, Marchevsky AM, Travis WD,. Updated protocol for the examination of specimens from patients with carcinoma of the lung. Arch Pathol Lab Med 2003; 127: 1304-1313.
10. Silverman JF,. Lung. Hong Kong: Churchill Livingstone Inc.; 1996.
11. Vazquez MF, Koizumi JH, Henschke CI, Yankelevitz DF,. Reliability of cytologic diagnosis of early lung cancer. Cancer 2007; 111: 252-258. (Pubitemid 47301284)
12. Kalhor N, Zander DS, Liu J,. TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material. Mod Pathol 2006; 19: 1117-1123. (Pubitemid 44106727)
13. Shidham VB, Lindholm PF, Kajdacsy-Balla A, Chang CC, Komorowski R,. Methods of cytologic smear preparation and fixation. Effect on the immunoreactivity of commonly used anticytokeratin antibody AE1/AE3. Acta Cytol 2000; 44: 1015-1022.
14. Liu J, Farhood A,. Immunostaining for thyroid transcription factor-1 on fine-needle aspiration specimens of lung tumors: A comparison of direct smears and cell block preparations. Cancer 2004; 102: 109-114. (Pubitemid 38489968)
15. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008; 32: 810-827.
16. Kim YH, Ishii G, Goto K, et al. Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. Clin Cancer Res 2004; 10: 7311-7317. (Pubitemid 39487720)